Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DZNeP||3-Deazaneplanocin A||EZH2 inhibitor 18||DZNeP (3-Deazaneplanocin A) inhibits S-adenosylhomocysteine hydrolase, resulting in depletion of EZH2 and inhibition of H3K27 methylation, which may promote apoptosis in cancer cells (PMID: 3790170, PMID: 19638619, PMID: 32508971).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EZH2 Y641S||diffuse large B-cell lymphoma||decreased response||DZNeP||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with DZNeP resulted in a slight increase in number of dead or sub-G1 cells and accumulation of DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).||25605023|
|SMARCB1 negative||atypical teratoid rhabdoid tumor||sensitive||DZNeP||Preclinical||Actionable||In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).||23190500|
|EZH2 Y641N||diffuse large B-cell lymphoma||predicted - sensitive||DZNeP||Preclinical - Cell culture||Actionable||In a preclinical study, DZNeP treatment resulted in an increase in the number of dead or sub-G1 cells and increased DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).||25605023|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|